Andere talen Athira Pharma, Inc.

Aandelen

ATHA

US04746L1044

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,01 ^USD	-1,47%		-4,74%	-17,28%

15/04	Athira Pharma, Inc. Benoemt Javier San Martin, M.D., tot Chief Medical Officer	CI
11/04	Athira Pharma, Inc. Kondigt de publicatie aan van preklinische gegevens die de behandeling met fosgonimeton in modellen van de ziekte van Alzheimer ondersteunen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer	15/04
Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	15/04
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's disease	12/04
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	11/04
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	11/04
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	11/04
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting	03/04
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference	08/03
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates	22/02
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	08/02
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	08/02
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis	08/02
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update	08/01
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update	08/01
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook	08/01
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer	08/01
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease	03/01
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease	03/01
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Athira Pharma, Inc.

Aandelen

ATHA

US04746L1044

Andere talen

Filters